Coherus Biosciences (NASDAQ:CHRS) has been assigned a $28.00 price objective by stock analysts at HC Wainwright in a research note issued to investors on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 134.70% from the stock’s current price.
CHRS has been the subject of several other research reports. BidaskClub downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. ValuEngine downgraded shares of Coherus Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, September 14th. Zacks Investment Research raised shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Cowen reaffirmed a “buy” rating and set a $45.00 target price on shares of Coherus Biosciences in a report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $27.20.
Shares of CHRS opened at $11.93 on Monday. Coherus Biosciences has a one year low of $8.05 and a one year high of $20.66. The stock has a market capitalization of $834.20 million, a PE ratio of -2.66 and a beta of 3.72. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 1.66.
Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04). On average, research analysts forecast that Coherus Biosciences will post -3.03 earnings per share for the current fiscal year.
In related news, Director James Healy sold 25,000 shares of Coherus Biosciences stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $20.50, for a total transaction of $512,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barbara K. Finck sold 1,760 shares of Coherus Biosciences stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $19.02, for a total transaction of $33,475.20. The disclosure for this sale can be found here. Insiders have sold a total of 28,520 shares of company stock valued at $578,676 in the last ninety days. 19.57% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. bought a new stake in shares of Coherus Biosciences during the 1st quarter worth about $115,000. Tower Research Capital LLC TRC bought a new stake in Coherus Biosciences in the 2nd quarter valued at about $118,000. Hartwell J M Limited Partnership bought a new stake in Coherus Biosciences in the 2nd quarter valued at about $140,000. Dynamic Technology Lab Private Ltd bought a new stake in Coherus Biosciences in the 2nd quarter valued at about $193,000. Finally, BlueMountain Capital Management LLC bought a new stake in Coherus Biosciences in the 2nd quarter valued at about $214,000. 91.25% of the stock is owned by institutional investors and hedge funds.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Read More: Balance Sheet
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.